Stockholm headquartered Bactiguard has entered into an exclusive, global license agreement for orthopedic trauma implants with US based Zimmer Biomet. The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royalties on net sales following commercialization.

"Our new, global partnership has the potential of expanding Bactiguard's current license business significantly and making a substantial contribution to our license revenues, both in the near term and in a longer perspective. It also confirms the value of the Bactiguard technology in a new application and global context, which makes me both happy and proud," says Christian Kinch, CEO.

Orthopedic trauma implants with Bactiguard's infection preventive technology were CE marked in December 2018 and will be used as a reference in the process of obtaining regulatory clearance.

According to the Orthopaedic Industry Annual Report®, the global orthopedics market was valued at USD 51 billion in 2018, where the orthopedic trauma segment accounted for 14 percent of those sales.

In 2018, Zimmer Biomet generated net sales of close to USD 8 billion.